Stem Cell Therapeutics for Oncology: Technologies and Global Markets

May 26, 2011

Wellesley, Mass. – According to a new technical market research report, STEM CELL THERAPEUTICS FOR ONCOLOGY: TECHNOLOGIES AND GLOBAL MARKETS (BIO075A) from BCC Research (www.bccresearch.com), the value of the market for stem cell therapeutics for oncology was more than $859 million in 2010, but is expected to increase to nearly $1.5 billion in 2015, for a five-year compound annual growth rate (CAGR) of 11.3%.

The largest regional segment of the market, North America, is projected to increase at a CAGR of 8% to reach nearly $510 million in 2015, after being valued at $347 million in 2010.

The second-largest segment, Europe, is estimated at nearly $261 million in 2010, but is expected to increase at a CAGR of 11.6% to reach $450 million in 2015.

The third-largest segment, made up of Latin and South America, is expected to reach $110 million in 2015, after rising at a CAGR of 15.1% from its estimated value of nearly $55 million in 2010.

The segment made up of Asia and all others is expected to increase from nearly $198 million in 2010 to nearly $399 million in 2015 at a CAGR of 15.1%.

At present, stem cell-based therapies in oncology are primarily of the hematopoietic variety, although at the research level there is significant development with embryonic, pluripotent and other stem cell therapies. Conservatively speaking, there are currently no FDA-approved stem cell biologics; however, there are a few FDA-approved therapies that are utilized adjunctively as part of an oncology regimen. These therapies have either a tissue-regenerative effect, a tissue-protective effect, or an anticancer effect, and are stem or progenitor cell-based depending on which theory of cellular biology is employed.

BCC’s key objective with this report is to produce an intensive analysis of the current stem cell therapeutics oncology market in cancers such as multiple myeloma, leukemia, lymphoma, prostate, breast and lung cancers, and to explore the future direction of these markets. These are the primary cancers being studied for applications relating to stem cell-based therapies.

This study will be of significant interest to hospitals, pharmacies, pharmaceutical companies,  biopharmaceutical researchers, pharmaceutical company marketing executives, contract research organizations, chemists,  physicians, nurses, physician assistants, pharmaceutical directors, product managers and representatives, all manner of institutional directors ranging from nursing homes and schools, to those in long-term care  situations, both public and private. It also will be of interest to investment bankers in the biotechnology and pharmaceutical sectors, insurance executives and oncology product marketing managers alike.

To Contact us, click here  

Stem Cell Therapeutics for Oncology: Technologies and Global Markets( BIO075A )
Publish Date: Mar 2011    

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.